On Monday, shares in Irvine, California headquartered Endologix Inc. ended the session 2.03% lower at $6.76 with a total volume of 867,556 shares traded. Endologix's shares have advanced 4.81% in the past one month. The stock is trading 3.04% above its 50-day moving average. Moreover, shares of the Company, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have a Relative Strength Index (RSI) of 52.20. ELGX complete research report is just a click away and free at:
Franklin Lakes, New Jersey headquartered Becton, Dickinson and Co.'s stock finished Monday's session 0.29% higher at $178.55 with a total volume of 441,788 shares traded. Over the last one month and the previous three months, Becton, Dickinson and Co.'s shares have advanced 2.92% and 2.13%, respectively. Furthermore, the stock has gained 29.83% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 4.88% and 4.73%, respectively. Shares of the Company, which develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide, are trading at a PE ratio of 29.67. Additionally, the stock has an RSI of 65.15. The complimentary report on BDX can be downloaded at:
On Monday, shares in Ewing, New Jersey headquartered Antares Pharma Inc. recorded a trading volume of 268,177 shares. The stock ended the day 0.44% higher at $2.29. Antares Pharma's stock has gained 4.09% in the last one month and 27.93% in the previous three months. Furthermore, the stock has rallied 151.65% in the past one year. The Company is trading above its 50-day and 200-day moving averages by 5.26% and 50.56%, respectively. Furthermore, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide, have an RSI of 59.47. Sign up for your complimentary research report on ATRS at:
Morrisville, North Carolina headquartered TransEnterix Inc.'s stock lost 2.90%, to close the day at $1.34. The stock recorded a trading volume of 581,067 shares, which was above its three months average volume of 549,430 shares. TransEnterix's shares are trading 6.89% and 11.84% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which focuses on the development and commercialization of surgical robotic systems, have an RSI of 37.93.
On January 19th, 2017, research firm Raymond James downgraded the Company's stock rating from 'Outperform' to 'Market Perform'. Get free access to your research report on TRXC at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA